immunotherapy

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and…

3 weeks ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor…

3 weeks ago

AltruBio Announces Formation of Scientific Advisory Board

World-renowned researchers with extensive experience in immunology and autoimmune diseases join AltruBio to support scientific advancements and pipeline development Photo…

3 weeks ago

Defence’s Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

4 weeks ago

Award-Winning CMUH (Taiwan) Excels at HIMSS, Leading Taiwan’s Smart Healthcare Transformation

TAICHUNG, Nov. 27, 2024 /PRNewswire/ -- In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, China Medical University Hospital (CMUH) established…

4 weeks ago

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy…

4 weeks ago

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

4 weeks ago

How AI-Driven EHR Solutions from ModuleMD Are Transforming Specialty Practices

GRAND BLANC, Mich., Nov. 25, 2024 /PRNewswire/ -- As healthcare faces increasing demands for precision and efficiency, specialty practices like…

4 weeks ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,…

1 month ago

Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies…

1 month ago